QTRX — Quanterix Corporation

Is QTRX overbought or oversold? Here is the current MarketMoodz read.

Healthcare · Medical Devices

Oversold As of November 17, 2026

Quanterix Corporation (QTRX) currently reads Oversold on the MarketMoodz overbought/oversold meter, as of November 17, 2026. The Healthcare name (Medical Devices) last closed at $2.84. The rating moved from Neutral to Oversold on November 14, 2026.

See all oversold Healthcare stocks →

AI analysis

Quanterix operates a differentiated ultra-sensitive biomarker detection platform that provides a clear technical advantage in select research and clinical applications. Commercial progress hinges on instrument placements and consumable sales that drive recurring revenue; execution on assay development and partnerships will determine near-term growth. Financially, the company has a history of operating losses and has relied on capital markets, making dilution and refinancing risk meaningful considerations. Competitive pressure from larger diagnostics players and potential reimbursement/regulatory hurdles add downside vulnerability. Absent fresh, material commercial wins or meaningfully improved cash visibility, the equity is likely to trade on execution and financing headlines in the near term.

Key factors

  • Proprietary Simoa digital immunoassay platform with niche position in ultra-sensitive biomarker detection supports differentiated product offering and recurring reagent/service revenue potential.
  • Revenue growth has been uneven historically; near-term top-line visibility depends on instrument placement, reagent consumption, and adoption in clinical/research workflows.
  • Balance sheet and cash burn dynamics are central — history of operating losses and prior financing activity increase sensitivity to capital markets and issuance decisions.
  • Sector environment: investor preference for growth names but rising convertible-debt/financing pressure in diagnostics/biotech increases dilution risk for mid/small-cap peers.
  • Potential commercial catalysts include expanded instrument placements, new assay launches or collaborations with large pharma/diagnostics partners and increased adoption across clinical studies.

Risks

  • Dilution and financing risk from convertible debt or equity raises that could depress share value and increase hedging pressure.
  • Competition from larger diagnostics and life-science instrument companies with broader commercial channels and scale.
  • Reimbursement, slow clinical adoption, or lower-than-expected reagent/consumable consumption per installed base reducing recurring revenue.
  • Macroeconomic or sector derisking that shifts capital away from high-growth diagnostics and extends cash runway concerns.
  • Regulatory setbacks for key assays or failures to secure necessary clearances for clinical expansion could slow commercialization.
  • Limited social media/research visibility increases susceptibility to swings from episodic newsflow rather than persistent investor conviction.

See today's live rating, score and targets

Members see the live hourly rating for QTRX — the numeric AI score plus targets and entry zones — while this public page updates nightly.

Start the 14-day trial

This page is for informational purposes only and is not investment, financial, tax, or legal advice. Ratings and research outputs can be wrong, incomplete, or stale. Past performance does not guarantee future results. Always do your own research and consider consulting a qualified professional.